Kathryn Hayashi

Kathryn Hayashi is President and CEO of TRIUMF Innovations, the business interface and commercialization arm, connecting TRIUMF, Canada’s particle accelerator centre, to the private sector via industry partnerships, licensing, and company creation.

Ms. Hayashi has more than 25 years of operational and strategic planning, finance, and governance experience in not-for-profit organizations, public and private companies, start-ups, and commercialization accelerators/incubators.

Ms. Hayashi is also the Co-Lead (with CPDC) for the Canadian Medical Isotope Ecosystem (CMIE), a national initiative that is dedicated to strengthening the Canadian medical isotope sector by providing resources to connect organizations, create new jobs, and fund next generation medical isotope programs through its development fund (CMIEDF).

Prior to TRIUMF Innovations, she was the Founding Chief Financial Officer of The Centre for Drug Research and Development (now adMare BioInnovations), Canada’s national drug development and commercialization engine. In addition to her work establishing CDRD as a leader in pre-clinical translational research and commercialization, Ms. Hayashi serves as a Director and Audit Committee Chair of the Center for Commercialization and Cancer Immunotherapy at the Hôpital Maisonneuve-Rosemont, as well as the Discovery Parks technology incubator, and Michael Smith Health Research BC, and has served on the boards of several spinoff companies. She also holds a Chartered Professional Accountant (CPA) designation.

---